Literature DB >> 1087316

The induction of hapten-specific T cell tolerance by using hapten-modified lymphoid cells. I. Characteristics of tolerance induction.

S D Miller, H N Claman.   

Abstract

BALB/c mice were made tolerant to the T cell-dependent phenomenon of contact sensitivity to DNFB by i.v. injection of syngeneic lymphoid cells which had been previously modified with DNFB in vitro. The highly efficient unresponsiveness, as measured by ear challenge and in vitro antigen-induced cell proliferation, was shown to follow dose-response kinetics both in vivo and in vitro and to be exquisitely specific for the DNP moiety. The kinetics of tolerance induction were shown to be very rapid and had been previously shown to be long lasting. Unresponsiveness was more efficient when the hapten-modified cells were introduced by the i.v. route and tolerance could be increased by repeated injection of tolerogen. The tolerance could be transferred to normal syngeneic recipients by spleen and/or lymph node cells from tolerant donors. A wide variety of hapten-modified lymphoid cells, including mixed cell populations and enriched populations of T cells, B cells, and macrophages, were capable of inducing tolerance. The unresponsiveness was dependent merely on the association of DNP to the lymphoid membrane proteins and not upon the viability of the hapten-modified cells. These experiments support the hypothesis that in hapten-specific T cell sensitivity, as exemplified by contact sensitivity to DNFB, specific T cell tolerance in actively induced by hapten on self-membrane. In other hapten-specific antibody-forming systems, tolerance appears to be most readily induced by hapten on soluble self protein or on a nonimmunogeneic carrier.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1087316

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Different forms of membrane-associated herpes simplex virus glycoproteins induce functionally distinct subsets of herpes simplex virus-specific suppressor T cells.

Authors:  G Y Ishioka; L I Pizer; J W Moorhead
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

2.  Induction of sensitization and tolerance in contact sensitivity with haptenated epidermal cells in the guinea-pig.

Authors:  D Baker; D Parker; D G Healey; J L Turk
Journal:  Immunology       Date:  1987-12       Impact factor: 7.397

3.  Regulation of cellular and humoral immune responses to collagen type I or collagen type II.

Authors:  L Butler; B Simmons; J Zimmerman; P Deriso; K Phadke; J Hom
Journal:  Immunology       Date:  1988-04       Impact factor: 7.397

4.  Regulation of lymphocyte proliferation in contact sensitivity: homeostatic mechanisms and a possible explanation of antigenic competition.

Authors:  I Kimber; C J Shepherd; J A Mitchell; J L Turk; D Baker
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

5.  Accessory cell presentation of hapten-modified self.

Authors:  J P Cogswell; D W Scott
Journal:  Surv Immunol Res       Date:  1985

6.  Studies on the recovery from tolerance to tumor antigens. I. Bone marrow cells from tolerant hosts are not rendered tolerant, but provide potential to reconstitute tumor-specific effector T cell clones.

Authors:  H Fujiwara; S Sato; A Kosugi; M Fukuzawa; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 7.  The role of contrasuppressor T cells in the adoptive transfer of contact sensitivity responses to picryl chloride.

Authors:  W Ptak; A Friedman; M Bereta; J Marcinkiewicz; B Horvat; P Reuter; D R Green; P M Flood
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

8.  Induction of contact sensitivity. Selective induction of delayed hypersensitivity by the injection of cells from draining lymph nodes into the footpads of normal recipients.

Authors:  W R Thomas; G L Asherson; M A Perera
Journal:  Immunology       Date:  1978-04       Impact factor: 7.397

9.  T-cell repopulation following neonatal injection of non-obese diabetic (NOD) mice with anti-T-cell antibodies.

Authors:  A Hayward; M Shriber; R Kubo; M McDuffie
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

10.  Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.

Authors:  M Lotem; T Peretz; O Drize; Z Gimmon; D Ad El; R Weitzen; H Goldberg; I Ben David; D Prus; T Hamburger; E Shiloni
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.